Aveanna Healthcare (NASDAQ:AVAH) Insider Patrick Cunningham Sells 17,965 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 17,965 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $7.38, for a total value of $132,581.70. Following the transaction, the insider directly owned 356,191 shares of the company’s stock, valued at $2,628,689.58. This represents a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock traded down $0.16 during trading hours on Friday, hitting $7.26. The stock had a trading volume of 182,739 shares, compared to its average volume of 1,229,020. Aveanna Healthcare Holdings Inc. has a fifty-two week low of $3.67 and a fifty-two week high of $10.32. The company has a market cap of $1.52 billion, a PE ratio of 20.32 and a beta of 2.06. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. The company has a 50-day moving average of $8.48 and a two-hundred day moving average of $8.44.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AVAH. Jefferies Financial Group upped their price objective on Aveanna Healthcare from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Tuesday, October 28th. UBS Group boosted their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. BMO Capital Markets initiated coverage on Aveanna Healthcare in a report on Thursday, November 13th. They set an “outperform” rating and a $11.00 price objective on the stock. Zacks Research lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Finally, Barclays boosted their target price on Aveanna Healthcare from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.06.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Insiders still retain meaningful stakes — despite the sales, CEO Jeff Shaner, CFO Matthew Buckhalter and other insiders continue to hold multi‑million‑dollar positions, which may signal ongoing alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest data shows zero shares (likely a data/reporting anomaly), so there’s no clear short‑selling pressure indicated by that statistic. Short Interest
• Neutral Sentiment: Today’s trading volume was well below the recent average, which can amplify price moves when large block trades or news hit the tape. (Context from recent price/volume data.)
• Negative Sentiment: Large, concentrated insider selling across Feb. 17–19: CEO Jeff Shaner sold roughly 461,900 shares across the three days (totaling about $3.4M), other executives including an additional director and senior officers sold substantial blocks, and cumulative insider disposals during the period totalled in the high hundreds of thousands of shares — a clear negative catalyst that likely pushed the stock down. See CEO filings. CEO Sales SEC Filing
• Negative Sentiment: Multiple additional executive/director sales (CFO, CAO, and other insiders sold across the same dates), including material dispositions by Edwin C. Reisz and Patrick A. Cunningham, reinforcing a market interpretation that insiders are taking profits or reducing exposure at current levels. Example filings here. Other Insider Filings
• Negative Sentiment: Coverage/analysis noting the drop: independent commentary flagged the same insider selling as the primary reason for a recent ~5.7% pullback, reinforcing market attention on the sales. AAII Article

Hedge Funds Weigh In On Aveanna Healthcare

A number of hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Aveanna Healthcare during the second quarter worth approximately $43,000. MQS Management LLC acquired a new stake in shares of Aveanna Healthcare during the 2nd quarter worth $59,000. Belvedere Trading LLC bought a new stake in Aveanna Healthcare during the second quarter worth about $62,000. Oxford Asset Management LLP acquired a new stake in Aveanna Healthcare during the second quarter worth about $64,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Aveanna Healthcare in the 2nd quarter valued at about $68,000. 87.96% of the stock is owned by institutional investors.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.